Literature DB >> 1281225

Effects of EGF-dextran-tyrosine-131I conjugates on the clonogenic survival of cultured glioma cells.

A Andersson1, J Capala, J Carlsson.   

Abstract

Epidermal growth factor, EGF, and 131I or 125I-labelled tyrosine were conjugated to the sugar polymer dextran. The conjugates bound to EGF-receptor rich human glioma cells in culture and the binding was mainly receptor specific because cells presaturated with nonradioactive EGF gave strongly reduced binding. The 131I labelled conjugates were used in tests on cellular retention and therapeutical effects. 131I activity delivered to the cells as EGF-dextran-tyrosine-131I remained cell-associated for much longer periods of time than 131I activity delivered by only EGF. The amount of cell-associated 131I activity was nearly constant for up to 25 hours. The 131I labelled conjugate gave, after a one hour incubation period for binding followed by a 25 hour incubation in nonradioactive medium, a good therapeutical effect. This effect, which corresponded to about 3.0 Gy of external 60Co radiation, was due to the specifically bound 131I. The comparatively small effects of nonbound 131I in the culture medium, present only during the first incubation hour, were measured in control experiments with presaturated receptors and were corrected for in the evaluation of the EGF-receptor mediated effects. Control experiments showed that neither nonradioactive EGF nor non-radioactive EGF-dextran conjugates gave measurable effects on clonogenic growth. The results obtained were promising and the possibilities to use EGF-dextran conjugates for therapy should be further examined.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1281225     DOI: 10.1007/BF00172597

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  41 in total

Review 1.  Epidermal growth factor: the receptor and its function.

Authors:  G Todderud; G Carpenter
Journal:  Biofactors       Date:  1989-03       Impact factor: 6.113

2.  Selective killing of squamous carcinoma cells by an immunotoxin that recognizes the EGF receptor.

Authors:  S Ozawa; M Ueda; N Ando; O Abe; S Minoshima; N Shimizu
Journal:  Int J Cancer       Date:  1989-01-15       Impact factor: 7.396

3.  Biodistribution of radioactive epidermal growth factor in normal and tumor bearing mice.

Authors:  C Mateo de Acosta; E Justiz; L Skoog; A Lage
Journal:  Anticancer Res       Date:  1989 Jan-Feb       Impact factor: 2.480

4.  Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin.

Authors:  T A Libermann; H R Nusbaum; N Razon; R Kris; I Lax; H Soreq; N Whittle; M D Waterfield; A Ullrich; J Schlessinger
Journal:  Nature       Date:  1985 Jan 10-18       Impact factor: 49.962

5.  Suppression of the growth of human colorectal carcinoma cells (LS174T) by radiolabeled monoclonal antibody (131I-MAbC27) in tissue culture and nude mice.

Authors:  L C Tsai; J K Lin; S H Han; H M Chen
Journal:  Dis Colon Rectum       Date:  1988-10       Impact factor: 4.585

6.  131I-anticarcinoembryonic antigen therapy of LS174T human colon adenocarcinoma spheroids.

Authors:  V K Langmuir; J K McGann; F Buchegger; R M Sutherland
Journal:  Cancer Res       Date:  1989-06-15       Impact factor: 12.701

7.  Toxicity of ligand and antibody-directed ricin A-chain conjugates recognizing the epidermal growth factor receptor.

Authors:  A M Vollmar; D E Banker; J Mendelsohn; H R Herschman
Journal:  J Cell Physiol       Date:  1987-06       Impact factor: 6.384

Review 8.  Structural basis for epidermal growth factor receptor function.

Authors:  J J Hsuan; G Panayotou; M D Waterfield
Journal:  Prog Growth Factor Res       Date:  1989

Review 9.  The solution structures of epidermal growth factor and transforming growth factor alpha.

Authors:  I D Campbell; R M Cooke; M Baron; T S Harvey; M J Tappin
Journal:  Prog Growth Factor Res       Date:  1989

10.  125I-labeled human epidermal growth factor. Binding, internalization, and degradation in human fibroblasts.

Authors:  G Carpenter; S Cohen
Journal:  J Cell Biol       Date:  1976-10       Impact factor: 10.539

View more
  1 in total

Review 1.  Planning for intracavitary anti-EGFR radionuclide therapy of gliomas. Literature review and data on EGFR expression.

Authors:  J Carlsson; Z P Ren; K Wester; A L Sundberg; N E Heldin; G Hesselager; M Persson; L Gedda; V Tolmachev; H Lundqvist; E Blomquist; M Nistér
Journal:  J Neurooncol       Date:  2006-03       Impact factor: 4.130

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.